Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telitacicept - Yantai Rongchang Pharmaceutical

Next Previous
Drug Profile

Telitacicept - Yantai Rongchang Pharmaceutical

Alternative Names: RC-18; RCT-18; Tai’ai

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RemeGen
  • Class Antirheumatics; Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins; Urologics
  • Mechanism of Action B cell activating factor inhibitors; Immunomodulators; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myasthenia gravis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Preregistration IgA nephropathy; Sjogren's syndrome
  • Phase III Neuromyelitis optica
  • Phase II Lupus nephritis; Multiple sclerosis

Most Recent Events

  • 25 Nov 2025 RemeGen plans a phase III trial for Myasthenia gravis in November 2025 (SC) (NCT07249632)
  • 13 Nov 2025 Adverse events and efficacy data from a phase III trial in IgA Nephropathy released by Vor Bio
  • 29 Oct 2025 Efficacy and adverse events data from a phase III trial in Myasthenia gravis released by Vor Bio

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top